China pharma to launch highly purified nmn+pqq product

Haikou, china, june 9, 2021 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, today announced plans to launch a highly purified nmn+pqq product following the recent successful completion of a pilot scale test. Β-nicotinamide mononucleotide (nmn) is a derivative of the b-vitamin niacin, which is believed to significantly improve health and wellness.
CPHI Ratings Summary
CPHI Quant Ranking